Conversely, decreasing GRK2 during a HFD via tamoxifen-induced genetic depletion prevents hepatic steatosis and liver inflammation and preserves insulin sensitivity [15], whereas global GRK2 hemizygous mice present lower signs of inflammation, less macrophage infiltration, and more active mitochondrial biogenesis and dynamics after MCD [23]. The gene discussed is GRK2; the disease is Hepatic steatosis.